TMPO and hepatocellular carcinoma: Sorafenib was selected as the positive control because it is a clinically validated first-line standard treatment for advanced hepatocellular carcinoma (HCC), with well-documented immunomodulatory activity that is partially dependent on T cell function—making it an appropriate control for confirming the specificity of TP5’s T cell-dependent mechanism [14,15].